Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$0.95 and traded as high as C$1.80. Oncolytics Biotech shares last traded at C$1.73, with a volume of 245,934 shares trading hands.
Analysts Set New Price Targets
Separately, Jones Trading downgraded shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.
View Our Latest Stock Report on ONC
Oncolytics Biotech Stock Performance
The firm's 50-day moving average price is C$0.92 and its 200 day moving average price is C$0.94. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The company has a market cap of C$128.71 million, a price-to-earnings ratio of -4.65 and a beta of 1.35.
Insider Buying and Selling
In other news, Senior Officer Jared Ryan Kelly acquired 50,400 shares of Oncolytics Biotech stock in a transaction that occurred on Wednesday, July 16th. The shares were acquired at an average price of C$1.63 per share, with a total value of C$82,284.50. Also, Senior Officer Thomas Heineman purchased 15,000 shares of the business's stock in a transaction on Thursday, July 17th. The stock was bought at an average cost of C$1.74 per share, for a total transaction of C$26,098.50. Insiders have bought 108,300 shares of company stock valued at $178,192 in the last 90 days. 3.82% of the stock is owned by insiders.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access